The global wound gel market size was valued at USD 6.05 billion in 2024 and is projected to reach USD 9.68 billion by 2033, growing at a CAGR of 5.37% from 2025 to 2033. The demand for wound gel is rising owing to the increasing number of surgical cases and the growing burden of wounds.
The rising number of surgical procedures worldwide
is a significant driver for expanding the wound gels market. Surgical
interventions often result in acute wounds that require effective
post-operative care to minimize infection risk and promote faster healing.
Advanced wound care products, particularly wound gels, are increasingly
preferred due to their ability to maintain a moist wound environment, support
autolytic debridement, and accelerate tissue regeneration. According to data
published in the BMC Surgery journal in 2025, approximately 313 million
surgical procedures are performed globally annually. This substantial volume
underscores the growing demand for reliable and effective wound care solutions,
reinforcing the critical role of wound gels in the post-surgical healing
process.
List of Key Players in the Wound Gel Market
- Medline Industries, LP.
- Coloplast Ltd
- Mölnlycke Health Care AB
- Solventum
- Convatec Inc.
- Smith+Nephew
- B. Braun SE
- DermaRite Industries, LLC.
- Integra LifeSciences Corporation
- Axio Biosolutions Private Limited
- Sanara MedTech Inc
Request a free sample copy or view report summary: Wound
Gel Market
Wound Gel Market Report Highlights
- The dressings segment dominated the wound gel industry in 2024, driven
by continuous innovation in advanced materials such as hydrogel, gelling
fiber, and specialty formulations like honey and silicone gel dressings.
- The silver (Ag+) segment held the largest market share in 2024
within the antimicrobial properties segment, demonstrating its leading
role in advanced wound care. It is also anticipated to grow fastest over
the forecast period.
- The chronic wounds segment dominated the market in 2024, capturing
the largest share of 55.29%. This dominance is attributed to the high
prevalence and significant healthcare burden associated with chronic
wounds.
- The offline segment held the largest market share in 2024. This dominance
is primarily attributed to the widespread availability of wound gel
products through hospitals, pharmacies, and medical supply stores, where
healthcare professionals often guide product selection.
- The hospital segment dominated the market in 2024, accounting for
the largest share of 41.52%. This dominance is due to the high volume of
patients requiring advanced wound care for acute and chronic conditions.
Wound Gel Market Segmentation
Grand View Research has segmented the global wound gel market
report based on product, antimicrobial properties, application, mode of
purchase, distribution channel, end use, and region:
·
Product Outlook (Revenue, USD Million, 2021 - 2033)
- Dressings
- Hydrogel
dressing
- Gelling
fiber dressings
- Others
- Gels
- Antimicrobial
Properties Outlook (Revenue, USD Million, 2021 - 2033)
- Silver
(Ag+)
- Non-Silver
- Mode of
Purchase Outlook (Revenue, USD Million, 2021 - 2033)
- Prescription
- Non-prescription
- Distribution
Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Offline
- Online
- Application
Outlook (Revenue, USD Million, 2021 - 2033)
- Chronic
Wounds
- Diabetic
Foot Ulcers (DFUs)
- Pressure
Ulcers
- Stage
1
- Stage
2
- Stage
3
- Stage
4
- Leg Ulcers
- Acute
Wounds
- Surgical
Incisions
- Burns
- 1st
Degree
- 2nd
Degree
- 3rd
Degree
- Lacerations,
Abrasions
- End Use
Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Specialty
Clinics
- Ambulatory
Surgery Centers
- Homecare
Settings
- Long-Term
Care Facilities
- Others
- Regional
Outlook (Revenue, USD Million, 2021-2033)
- North
America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia
Pacific
- Japan
- China
- India
- South
Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
Recent Developments
In March 2025, SolasCure announced the enrollment of
the first patient in its upcoming Phase II clinical trial to advance the
development of the Aurase Wound Gel. This marks a significant milestone in the
company’s efforts to evaluate the safety and efficacy of the gel in promoting
wound healing. The trial is designed to gather critical data supporting further
clinical development and potential regulatory approval of this innovative
treatment.
In March 2025, Mölnlycke Health Care completed the
acquisition of the manufacturer of Granudacyn. Granudacyn includes solutions
and gels designed explicitly for wound cleansing, irrigation, and moisturizing
across various wound types. This strategic acquisition strengthens Mölnlycke’s
portfolio, enhancing its capabilities to deliver comprehensive and effective
solutions for wound care and infection prevention.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
